Parkinson’s disease (PD) is one of the most common chronic neurodegenerative diseases in the elderly, and its prevalence is expected to grow 20% over the next decade as the general population ages. Despite the large and growing presence of generics in this market, several high-cost brands remain important to PD treatment, such as the MAO-B inhibitor Azilect (Teva’s rasagiline) and the dopamine agonist Neupro (UCB’s rotigotine), recently relaunched in the United States. Moreover, new premium-priced entrants from current drug classes (such as Newron Pharmaceuticals/Zambon Pharma/Meiji Seika Pharma’s safinamide), first-in-class agents (Acadia Pharmaceuticals’ pimavanserin), and novel reformulations (IPX-066 [Impax Laboratories’ Rytary]) are expected to launch over the next several years, targeting niche populations (e.g., patients experiencing motor response complications, PD-related psychosis). The evolving PD marketplace will make physicians’ treatment decisions more complex, while payers’ coverage decisions will likely be increasingly strained by the need to contain growing PD-related healthcare expenditures.
This primary-research based report presents and analyzes the results of a survey of 101 U.S. neurologists treating PD patients and 30 managed care organization (MCO) directors. The report explores key market access features and clinical factors impacting PD treatment today and in the future. In particular, we assess physicians’ and payers’ attitudes, expectations, receptivity, and reservations regarding current and emerging PD therapies.
This U.S. Physician &, Payer Forum report contains insights from a survey of 101 neurologists and 30 MCO pharmacy/medical directors regarding physician and payer dynamics that affect prescribing practices for the treatment of PD in the United States. In this report, we explore the use, reception, and formulary status of key current PD therapies by neurologists and MCO directors and gauge surveyed physician and payer outlook on four late-stage emerging therapies. By understanding the attitudes and expectations of prescribers and payers toward current and emerging PD therapies, stakeholders can gain an understanding of the complex PD treatment algorithm and the reimbursement climate for PD.
Markets covered: United States.
Primary research: Online survey of 101 neurologists and 30 MCO pharmacy or medical directors.
Epidemiology: 2012-2022 prevalent cases of PD in the United States.
Market analysis: 2012 U.S. market and patient share by drug class.